Zealand Pharma A/S
ZEAL
Rang in aandelen
#5479
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Aandeelprijs
$35.23
Marktkapitalisatie
$2.45B
Verandering (1 dag)
-1.68%
Verandering (1 jaar)
-50.79%
Land
DK
Handel Zealand Pharma A/S (ZEAL)
Categorie
Healthcare
Marktkapitalisatie van Zealand Pharma A/S(ZEAL)
Marktkapitalisatie: $2.45B
Vanaf October 2026 heeft Zealand Pharma A/S een marktkapitalisatie van $2.45B. Dit maakt Zealand Pharma A/S volgens onze gegevens het 5479th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Zealand Pharma A/S van 2013 tot 2026
ZEAL vergeleken met de top 5 populairste stocks
